Edition:
United States

Immutep Ltd (IMMP.OQ)

IMMP.OQ on NASDAQ Stock Exchange Global Market

2.34USD
14 Dec 2018
Change (% chg)

$0.01 (+0.43%)
Prev Close
$2.33
Open
$2.33
Day's High
$2.38
Day's Low
$2.32
Volume
1,996
Avg. Vol
20,388
52-wk High
$4.20
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Immutep Ltd Enters Into Clinical Trial Collaboration With Merck & Co
Sunday, 11 Mar 2018 05:20pm EDT 

March 12 (Reuters) - Immutep Ltd ::ENTERED INTO A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK & CO., INC.DEAL TO EVALUATE COMBINATION OF IMMUTEP'S IMMUNOTHERAPY PRODUCT CANDIDATE WITH MSD'S ANTI-PD-1 THERAPY KEYTRUDA IN A NEW CLINICAL TRIAL.  Full Article

Prima Biomed says Lucy Turnbull steps down as chairman​
Thursday, 16 Nov 2017 04:24pm EST 

Nov 17 (Reuters) - Prima Biomed Ltd ::Russell Howard appointed as chairman​.Lucy Turnbull steps down as chairman​.‍vice-Chairman Albert Wong to step down​.  Full Article

Prima Biomed files for offer and sale of up to 197.35 mln ordinary shares
Thursday, 19 Oct 2017 04:54pm EDT 

Oct 20 (Reuters) - Prima Biomed Ltd :Prima Biomed Ltd files for offer and sale of up to 197.35 million ordinary shares, represented by 1.97 million adss‍​ by selling shareholders - SEC filing.  Full Article

Prima Biomed ‍received approval for intiation of ‘Insight’ clinical trial
Sunday, 9 Jul 2017 09:18pm EDT 

July 10 (Reuters) - Prima Biomed Ltd :Received regulatory and ethical approvals for clinical trial investigating IMP321 in new settings, called Insight​.Approval has been received from Paul-Ehrlich-Institut, Federal Institute For Vaccines And Biomedicines For German Federal Ministry Of Health.  Full Article